Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 4:41 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 5,272 matching trials from the live ClinicalTrials.gov search.
Filters: Gainesville, Florida Clear all
Completed Phase 2 Interventional

A Study of Hepatitis C Virus (HCV) Polymerase Inhibitor Pro-Drug in Combination With PEGASYS With or Without COPEGUS in Patients With Chronic Hepatitis C (CHC) Genotype 1 Infection.

NCT00377182
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Copegus, PEGASYS, RO5024048 1500mg, RO5024048 3000mg
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
17
States / cities
La Jolla, California • Long Beach, California • Sacramento, California + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Nov 1, 2026, 4:41 AM EST
Recruiting Phase 3 Interventional

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

NCT06592924
View directory record Official record
Conditions
Prostate Cancer (Adenocarcinoma)
Interventions
Abiraterone, Enzalutamide, Apalutamide, Darolutamide (BAY 1841788), Docetaxel, ADT
Drug
Lead sponsor
Canadian Cancer Trials Group
Network
Eligibility
18 Years and older · Male only
Enrollment
830 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
374
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 272 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Nov 1, 2026, 4:41 AM EST
Completed Not applicable Interventional Results available

Deep Brain Stimulation (DBS) for the Suppression of Tremor

NCT02087046
View directory record Official record
Conditions
Tremor, Action Tremor, Essential Tremor, Tremor, Limb
Interventions
ANS Totally Implantable Deep Brain Stimulation System
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2017
U.S. locations
12
States / cities
Birmingham, Alabama • Loma Linda, California • Pasadena, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2023 · Synced Nov 1, 2026, 4:41 AM EST
Completed No phase listed Observational

Retrospective Chart Review of First-time Opsumit® (Macitentan) Users in the United States

NCT03197688
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Notapplicable
Other
Lead sponsor
Actelion
Industry
Eligibility
Not listed
Enrollment
2,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
105
States / cities
Phoenix, Arizona • La Jolla, California • Loma Linda, California + 89 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Nov 1, 2026, 4:41 AM EST
Completed Not applicable Interventional

Prospective Randomized Blinded Trial of VersaWrap Tendon Protector for Zone 2 Flexor Tendon Injuries

NCT04322370
View directory record Official record
Conditions
Flexor Tendon
Interventions
Standard of Care Surgical Procedure, VersaWrap Treatment
Procedure · Device
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 99 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Nov 1, 2026, 4:41 AM EST
Recruiting Phase 2 Interventional

Evaluating VM100 Nutritional Supplement for Improving Quality of Life in Duchenne Muscular Dystrophy Patients

NCT07766980
View directory record Official record
Conditions
Duchenne Muscular Dystrophy, Duchenne Disease, Muscular Dystrophy in Children, DMD, Muscular Dystrophy
Interventions
VM100 Nutritional Supplement
Drug
Lead sponsor
University of Florida
Other
Eligibility
6 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Nov 1, 2026, 4:41 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Swallowing Pressure Profiles in Healthy Adults

NCT03986554
View directory record Official record
Conditions
Healthy
Interventions
Videofluoroscopic swallow study, pharyngeal High Resolution Manometry
Procedure
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 45 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 17, 2020 · Synced Nov 1, 2026, 4:41 AM EST
Completed Phase 3 Interventional

THE BALANCE Study: Treatment of Hyponatremia Based on Lixivaptan in NYHA Class III/IV Cardiac Patient Evaluation

NCT00578695
View directory record Official record
Conditions
Hyponatremia
Interventions
lixivaptan, Placebo
Drug
Lead sponsor
CardioKine Inc.
Industry
Eligibility
18 Years and older
Enrollment
652 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
102
States / cities
Birmingham, Alabama • Mobile, Alabama • Bakersfield, California + 82 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2011 · Synced Nov 1, 2026, 4:41 AM EST
Recruiting Phase 2 Interventional

A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

NCT04322318
View directory record Official record
Conditions
Anaplastic Kidney Wilms Tumor, Recurrent Kidney Wilms Tumor, Stage II Kidney Wilms Tumor, Stage III Kidney Wilms Tumor, Stage IV Kidney Wilms Tumor
Interventions
Biopsy Procedure, Biospecimen Collection, Bone Scan, Carboplatin, Computed Tomography, Cyclophosphamide, Doxorubicin, Etoposide, Ifosfamide, Irinotecan, Magnetic Resonance Imaging, Positron Emission Tomography, Radiation Therapy, Surgical Procedure, Topotecan, Transabdominal Ultrasound, Vincristine, X-Ray Imaging
Procedure · Drug · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 30 Years
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
178
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 138 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Nov 1, 2026, 4:41 AM EST
Terminated Not applicable Interventional Results available

DEfibrillators To REduce Risk by MagnetIc ResoNance Imaging Evaluation

NCT00487279
View directory record Official record
Conditions
Coronary Artery Disease, Left Ventricular Dysfunction, Sudden Cardiac Death
Interventions
Defibrillator, Control
Device · Other
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
56
States / cities
Anchorage, Alaska • Tucson, Arizona • Glendale, California + 42 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2019 · Synced Nov 1, 2026, 4:41 AM EST
Completed Phase 3 Interventional Results available

An Open-Label Study to Compare the Lipid Effects of Niacin ER and Simvastatin (NS) to Atorvastatin in Subjects With Hyperlipidemia or Mixed Dyslipidemia (SUPREME)

NCT00465088
View directory record Official record
Conditions
Hyperlipidemia, Mixed Dyslipidemia
Interventions
Niacin ER/Simvastatin Tablets, atorvastatin
Drug
Lead sponsor
Abbott
Industry
Eligibility
21 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
46
States / cities
Anaheim, California • Huntington Park, California • Long Beach, California + 43 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2011 · Synced Nov 1, 2026, 4:41 AM EST
Completed Phase 3 Interventional Results available

12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)

NCT02107196
View directory record Official record
Conditions
Irritable Bowel Syndrome With Diarrhea
Interventions
Ibodutant 10 mg, Placebo
Drug
Lead sponsor
Menarini Group
Industry
Eligibility
18 Years and older · Female only
Enrollment
535 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
65
States / cities
Huntsville, Alabama • Sherwood, Arizona • Little Rock, Arkansas + 56 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Nov 1, 2026, 4:41 AM EST
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Participants With Spinal Muscular Atrophy

NCT05337553
View directory record Official record
Conditions
Spinal Muscular Atrophy, Neuromuscular Diseases, SMA
Interventions
taldefgrobep alfa, Placebo
Drug
Lead sponsor
Biohaven Pharmaceuticals, Inc.
Industry
Eligibility
4 Years to 21 Years
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
30
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Nov 1, 2026, 4:41 AM EST
Active, not recruiting Phase 2Phase 3 Interventional

A Study of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME

NCT06957080
View directory record Official record
Conditions
Diabetic Macular Edema (DME)
Interventions
Remigromig, Ranibizumab
Drug
Lead sponsor
EyeBiotech Ltd.
Industry
Eligibility
18 Years and older
Enrollment
1,054 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
107
States / cities
Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 96 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 1, 2026, 4:41 AM EST
Completed Phase 3 Interventional

S0205 Gemcitabine w/ or w/o Cetuximab as First-Line Therapy in Locally Advanced Pancreas Cancer

NCT00075686
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
cetuximab, gemcitabine hydrochloride
Biological · Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
766 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
382
States / cities
Mobile, Alabama • Opelika, Alabama • Anchorage, Alaska + 276 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2015 · Synced Nov 1, 2026, 4:41 AM EST
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Zinc Supplementation Prior to Botox Injections for Spasmodic Dysphonia

NCT05892770
View directory record Official record
Conditions
Spasmodic Dysphonia
Interventions
Zinc gluconate supplement, Botulinum toxin type A
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 99 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Nov 1, 2026, 4:41 AM EST
Completed Phase 2 Interventional Results available

DOTS: Dalbavancin as an Option for Treatment of Staphylococcus Aureus Bacteremia

NCT04775953
View directory record Official record
Conditions
Staphylococcal Bacteraemia
Interventions
Cefazolin, Dalbavancin, Daptomycin, Nafcillin, Oxacillin, Vancomycin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
23
States / cities
Birmingham, Alabama • Sacramento, California • Torrance, California + 19 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Nov 1, 2026, 4:41 AM EST
Completed Phase 2Phase 3 Interventional Results available

Randomized Study of Laser and Balloon Angioplasty Versus Balloon Angioplasty to Treat Peripheral In-stent Restenosis

NCT01330628
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Turbo Elite Laser and Turbo Tandem Laser Guide Catheters, Balloon angioplasty
Device · Procedure
Lead sponsor
Spectranetics Corporation
Industry
Eligibility
18 Years to 85 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
33
States / cities
Birmingham, Alabama • Fairhope, Alabama • Little Rock, Arkansas + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2016 · Synced Nov 1, 2026, 4:41 AM EST
Active, not recruiting Phase 3 Interventional

Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability

NCT04804644
View directory record Official record
Conditions
Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Recurrent Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Magnetic Resonance Imaging, Memantine Hydrochloride, Neurocognitive Assessment, Stereotactic Radiosurgery, Survey Administration, Whole-Brain Radiotherapy
Procedure · Drug · Other + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
227
States / cities
Phoenix, Arizona • Anaheim, California • Bellflower, California + 172 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Nov 1, 2026, 4:41 AM EST
Active, not recruiting Not applicable Interventional

Surveillance AFter Extremity Tumor surgerY

NCT03944798
View directory record Official record
Conditions
Soft Tissue Sarcoma, Lung Metastases
Interventions
Frequency: Every 3 Months, Frequency: Every 6 Months, Imaging Modality: Chest Radiograph (CXR), Imaging Modality: Chest CT
Other
Lead sponsor
McMaster University
Other
Eligibility
18 Years and older
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
16
States / cities
Sacramento, California • Hartford, Connecticut • Gainesville, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2024 · Synced Nov 1, 2026, 4:41 AM EST
Completed Phase 1 Interventional

Diethylhomospermine (DEHSPM) for Refractory AIDS-Related Diarrhea

NCT00002121
View directory record Official record
Conditions
Diarrhea, HIV Infections
Interventions
Diethylhomospermine
Drug
Lead sponsor
VA Medical Center-Gainesville
Federal
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 1, 2026, 4:41 AM EST
Recruiting No phase listed Observational

Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry

NCT02071134
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Deep Brain Stimulation (DBS)
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2038
U.S. locations
29
States / cities
Aliso Viejo, California • Los Angeles, California • Aurora, Colorado + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Nov 1, 2026, 4:41 AM EST
Completed No phase listed Observational Accepts healthy volunteers

A Study of Physical and Metabolic Abnormalities in HIV Infected and Uninfected Children and Youth

NCT00069004
View directory record Official record
Conditions
HIV Infections, HIV-Associated Lipodystrophy Syndrome, HIV Lipodystrophy Syndrome, Lipodystrophy, Dyslipidemia, Osteoporosis, Osteopenia
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
7 Years to 25 Years
Enrollment
450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2005
U.S. locations
36
States / cities
Birmingham, Alabama • Alhambra, California • Long Beach, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2014 · Synced Nov 1, 2026, 4:41 AM EST
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Reference Values for Videofluoroscopic Measures of Swallowing

NCT05497219
View directory record Official record
Conditions
Dysphagia, Oropharyngeal
Interventions
Videofluoroscopic Swallowing Study (VF)
Diagnostic Test
Lead sponsor
University Health Network, Toronto
Other
Eligibility
18 Years and older
Enrollment
580 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
3
States / cities
Gainesville, Florida • Cincinnati, Ohio • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Nov 1, 2026, 4:41 AM EST